<?xml version="1.0" encoding="UTF-8"?>
<p>Combination therapy with lamivudine/IFNa (either concurrent or sequential) proved to be more effective than single drugs alone in adult patients with elevated ALT levels [
 <xref ref-type="bibr" rid="CR109">109</xref>]. Three studies in children investigated therapy in treatment-naïve children with elevated ALT levels. Although no difference was found between different combination strategies, the children reached 30–60 % seroconversion to anti-HBe and 9–17 % to anti-HBs [
 <xref ref-type="bibr" rid="CR110">110</xref>]. As no large clinical trials have been conducted so far, advantages of combination therapy over monotherapy in children are still unclear.
</p>
